Immunoediting and antigen loss: Overcoming the Achilles heel of immunotherapy with antigen non-specific therapies

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Monjazeb, Arta Monir ^a   Zamora, Anthony E ^a   Grossenbacher, Steven K ^a   Mirsoian, Annie ^a   Sckisel, Gail D ^a   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bystander T cells; Cancer immunotherapy; Immune suppression; Immune surveillance; Immune tolerance; Radiotherapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FALIMAREV; INTERLEUKIN 2; IPILIMUMAB; NITRIC OXIDE; ONAMELATUCEL L; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN LOSS; ANTIGEN SPECIFICITY; ANTIGENICITY; CANCER IMMUNOTHERAPY; CELL HETEROGENEITY; CELLULAR IMMUNITY; COLITIS; CYTOTOXICITY; DERMATITIS; ENDOCRINE DISEASE; HEPATITIS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LUNG EDEMA; MELANOMA; NONHUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SEPSIS; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VASCULAR DISEASE;

EID: 84890490882     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00197     Document Type: Review

References (75)

1. Erlich P. Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd (1909) 5:273-90.
2. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med (1964) 15:167-86. doi:10.1146/annurev.me.15.020164.001123
3. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 21(12):2415-32. doi:10.1200/JCO.2003.06.041
4. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol (2011) 186(3):1325-31. doi:10.4049/jimmunol.0902539
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363(5):411-22. doi:10.1056/NEJMoa1001294
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466
7. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 9(1):214. doi:10.1186/1479-5876-9-214
8. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov (2011) 10(8):591-600. doi:10.1038/nrd3500
9. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 110(9):3507-12. doi:10.1073/pnas.1222878110
10. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 102(18):1388-97. doi:10.1093/jnci/djq310
11. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A (2009) 106(46):19455-60. doi:10.1073/pnas.0909474106
12. Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 201(2):249-57. doi:10.1084/jem.20041378
13. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg (2006) 41(8):1361-8. doi:10.1016/j.jpedsurg.2006.04.034
14. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol (2010) 57(5):766-73.
15. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 361(19):1838-47. doi:10.1056/NEJMoa0810097
16. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271(12):907-13. doi:10.1001/jama.1994.03510360033032
17. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 13(3):688-96.
18. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 37(5):499-507. doi:10.1053/j.seminoncol.2010.09.007
19. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 18(4):843-51. doi:10.1038/mt.2010.24
20. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science (1977) 197(4306):893-5. doi:10.1126/science.887927
21. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366(10):883-92. doi:10.1056/NEJMoa1113205
22. Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 8(3):635-41. doi:10.1021/mp1004228
23. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 138(2):105-15. doi:10.1111/imm.12036
24. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 66(11):5527-36. doi:10.1158/0008-5472.CAN-05-4128
25. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 5(8):641-54. doi:10.1038/nri1668
26. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 117(5):1147-54. doi:10.1172/JCI31178
27. Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull (1964) 20:154-8.
28. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
29. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev (1971) 7:3-25.
30. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 138(3):989-95.
31. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science (2004) 305(5681):200-5. doi:10.1126/science.1100369
32. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365(8):725-33. doi:10.1056/NEJMoa1103849
33. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29(7):917-24. doi:10.1200/JCO.2010.32.2537
34. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 105(51):20410-5. doi:10.1073/pnas.0810114105
35. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 15(7):2507-13. doi:10.1158/1078-0432.CCR-08-2424
36. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol (2012) 189(7):3759-66. doi:10.4049/jimmunol.1201529
37. Chung MH, Gupta RK, Hsueh E, Essner R, Ye W, Yee R, et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol (2003) 21(2):313-9. doi:10.1200/JCO.2003.10.068
38. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3(11):991-8. doi:10.1038/ni1102-991
39. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-11. doi:10.1038/35074122
40. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 98(7):1633-41. doi:10.1172/JCI118958
41. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 99(25):16168-73. doi:10.1073/pnas.242600099
42. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 118(1):6-10. doi:10.1002/ijc.21303
43. Kasajima A, Sers C, Sasano H, Jöhrens K, Stenzinger A, Noske A, et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol (2010) 41(12):1758-69. doi:10.1016/j.humpath.2010.05.014
44. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 66(11):5910-8. doi:10.1158/0008-5472.CAN-05-3905
45. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2010) 463(7278):191-6. doi:10.1038/nature08658
46. Monjazeb AM, High KP, Koumenis C, Chilton FH. Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. Prostaglandins Leukot Essent Fatty Acids (2005) 73(6):463-74. doi:10.1016/j.plefa.2005.07.009
47. Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH. Arachidonic acid-induced gene expression in colon cancer cells. Carcinogenesis (2006) 27(10):1950-60. doi:10.1093/carcin/bgl023
48. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res (2008) 68(18):7520-9. doi:10.1158/0008-5472.CAN-08-1060
49. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother (2008) 57(6):813-21. doi:10.1007/s00262-007-0417-x
50. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374(6522):546-9. doi:10.1038/374546a0
51. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 93(7):2879-83. doi:10.1073/pnas.93.7.2879
52. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol (2012) 188(4):1592-9. doi:10.4049/jimmunol.1101304
53. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity (2009) 30(5):636-45. doi:10.1016/j.immuni.2009.04.010
54. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364(26):2517-26. doi:10.1056/NEJMoa1104621
55. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281(5380):1191-3. doi:10.1126/science.281.5380.1191
56. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 175(9):5601-5.
57. Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res (2010) 70(1):129-38. doi:10.1158/0008-5472.CAN-09-3170
58. Bauer S, Kirschning CJ, Häcker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 98(16):9237-42. doi:10.1073/pnas.161293498
59. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med (2004) 200(10):1325-35. doi:10.1084/jem.20041522
60. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol (2005) 175(4):2167-73.
61. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 22(3):113-24. doi:10.1016/j.smim.2010.03.001
62. Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, et al. Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy. Blood (2012) 119(13):3073-83. doi:10.1182/blood-2011-07-369736
63. Dhanji S, Teh HS. IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells. J Immunol (2003) 171(7):3442-50.
64. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 331(6024):1612-6. doi:10.1126/science.1198443
65. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science (1996) 272(5270):1947-50. doi:10.1126/science.272.5270.1947
66. Murali-Krishna K, Altman JD, Suresh M, Sourdive D, Zajac A, Ahmed R. In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection. Adv Exp Med Biol (1998) 452:123-42. doi:10.1007/978-1-4615-5355-7_14
67. Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med (1997) 185(7):1241-51. doi:10.1084/jem.185.7.1241
68. Dhanji S, Teh SJ, Oble D, Priatel JJ, Teh HS. Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors. Blood (2004) 104(7):2116-23. doi:10.1182/blood-2004-01-0150
69. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 170(5):2727-33.
70. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 13(3):354-60. doi:10.1038/nm1554
71. Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol (2012) 9(3):248-58. doi:10.3109/1547691X.2012.685527
72. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother (2011) 60(8):1137-46. doi:10.1007/s00262-011-1011-9
73. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Cancer Res (2008) 14(14):4532-42. doi:10.1158/1078-0432.CCR-07-4711
74. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol (2001) 19(18):3836-47.
75. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 17(3):718-30. doi:10.1245/s10434-009-0809-6